Programme
Sunday 21st September 2014 |
||
15:00 – 17:15 |
Registration & Reception |
|
17:30 – 17:50 |
Opening Comments |
|
Risk Assessment & Prevention |
||
17:50 – 18:10 |
Ian Graham |
NEW PERSPECTIVES ON CVD RISK ESTIMATION |
18:10 – 18:30 |
Nathan Wong |
RISK SCORING AND CVD RISK ASSESSMENT: ACC/AHA GUIDELINES |
18:30 – 18:50 |
Noureddine Chaouki |
OVERWEIGH AND OBESITY PROFILE IN MOROCCO AND OTHER CVD RISK FACTORS |
18:50 – 19:10 |
Laurence Sperling |
FOCUS ON CV HEALTH (NOT DISEASE) |
19:10 – 19:30 |
Panel Discussion |
|
19:30 – 20:00 |
Refreshments |
|
20:00 |
Group Dinner & Free Time |
Monday 22nd September 2014 |
||
Global Concepts in CVD Prevention and Newer Guidelines |
||
08:30 – 08:50 |
Shanthi Mendis |
THE GLOBAL CVD PREVENTION AGENDA |
08:50 – 09:10 |
Ian Graham |
THE GLOBAL CVD PREVENTION AGENDA: CAN EUROPE HELP? |
09:10 – 09:30 |
Kathryn Taubert |
GLOBAL PREVENTION OF CVD IN WOMEN |
09:30 – 09:50 |
Kathryn Taubert |
WHAT ARE THE ACHIEVABLE GOALS IN HEART HEALTH FOR CHILDREN? |
09:50 – 10:10 |
Panel Discussion |
|
10:10 – 10:40 |
Refreshments |
|
10:40 – 11:00 |
Nathan Wong |
DIABETES AND CVD: GUIDELINES FOR PREVENTION |
11:00 – 11:20 |
Maciej Banach |
PREHYPERTENSION AND IMPLICATIONS FOR GLOBAL CVD PREVENTION |
11:20 – 11:40 |
Handrean Soran |
THE IMPORTANCE OF CONSIDERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL RESPONSE, NUMBER NEEDED TO TREAT AS WELL AS CARDIOVASCULAR RISK IN DECIDING WHO CAN BENEFIT FROM STATIN THERAPY. |
11:40 – 12:00 |
Handrean Soran |
A COMPARISON OF LOW AND HIGH DOSE ATORVASTATIN ON ACHIEVING APOLIPOPROTEIN B100, LDL-C AND NON-HDL-C THERAPEUTIC TARGETS, HDL FUNCTIONALITY, MODIFIED LDL AND INFLAMMATORY CYTOKINES OVER ONE YEAR IN TYPE 2 DIABETES: THE PROTECTION AGAINST NEPHROPATHY IN DIABETES WITH ATORVASTATIN (PANDA) TRIAL |
12:00 – 12:20 |
Panel Discussion |
|
12:20 – 17:00 |
Group Lunch & Free Time |
|
14:00 – 17:00 |
Group Tour to El Jadida (optional) |
|
Guidelines for Europe and America: Understanding the Differences (Organised by EACPR) |
||
17:00 – 17:30 |
Ian Graham |
EUROPEAN GUIDELINES ON CVD PREVENTION |
17:30 – 17:50 |
Nathan Wong |
OVERVIEW OF ACC/AHA GUIDELINES FOR CVD PREVENTION |
17:50 – 18:10 |
Maciej Banach |
EUROPEAN AND AMERICAN GUIDELINES FOR HYPERTENSION MANAGEMENT: ARE THEY COMPATIBLE? |
18:10 – 18:30 |
Panel Discussion |
|
18:30 – 19:30 |
Moderated Poster Session & Cocktail Reception (3min per presenter) |
|
19:30 |
Group Dinner & Free Time |
Tuesday 23rd September 2014 |
||
CVD Prevention in Morocco |
||
08:30 – 08:50 |
Mohamed Alami |
CVD SCREEN AND PREVENTION EFFORTS IN MOROCCO |
08:50 – 09:10 |
Derouiche Abdelfettah |
NON-COMMUNICABLE DISEASES IN CASABLANCA-MOROCCO |
09:10 – 09:30 |
Habbal Rachida et al |
EPIDEMIOLOGICAL PROFILE OF THE HYPERTENSION AND THE ACCESION TO THE RECOMMENDATIONS OF THE MOROCCAN PATIENT |
09:30 – 10:00 |
Refreshments |
|
10:00 – 10:20 |
Habbal Rachida et al |
SERUM LIPID PROFILE IN HYPERTENSIVE PATIENTS IN THE UNIVERSITY HOSPITAL OF CASABLANCA |
10:20 – 10:40 |
Panel Discussion |
|
10:40 – 17:00 |
Group Lunch & Free Time |
|
Are Current Guidelines Relevant or Helpful? |
||
17:00 – 17:20 |
Ian Graham |
EUROPE |
17:20 – 17:40 |
Laurence Sperling |
USA |
17:40 – 18:00 |
Mohamed Alami |
GLOBAL RISK SCORING IN MOROCCO: WHAT IS NEEDED FOR MOROCCO? |
18:00 – 18:20 |
Panel Discussion |
|
18:20 – 19:00 |
Refreshments |
|
20:00 |
*Gala Night & Group Photo* |
Wednesday 24th September 2014 |
||
Moving Forward to Promote Prevention || The Future of Prevention |
||
08:30 – 08:50 |
Shanthi Mendis |
THE WHO PROGRAMME FOR THE CONTROL OF CVD AND OTHER CHRONIC DISEASES; ADDED VALUE FROM AN INTEGRATED APPROACH |
08:50 – 09:10 |
Ian Graham |
THE ROLE OF AUDIT IN CVD PREVENTION |
09:10 – 09:30 |
Kornelia Kotseva |
EUROASPIRE IV: FINDINGS AND IMPLICATIONS IN SECONDARY PREVENTION |
09:30 – 09:50 |
Panel Discussion |
|
09:50 – 10:30 |
Refreshments |
|
10:30 – 10:50 |
Yaakov Henkin |
IMPLEMENTING PREVENTION - LESSONS FROM THE EUROPEAN PREVENTION IMPLEMENTATION COMMITEE AND THE COUNTRY OF THE MONTH PROJECT |
10:50 – 11:30 |
Final Panel Discussion |
|
11:30 – 11:45 |
Closing Remarks (Chairs & Fusion) |